A Phase 2 interventional study of PF-04965842 and PF-04965842 in Atopic Dermatitis, sponsored by Pfizer. Completed at 64 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-02.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer
Ages 2–5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 150 across the 20 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
58 studies in Dermatitis, Atopic by Pfizer: 11 open now, 13 under way, 4 of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 17th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2016, is one of 13 in phase 2, and was the 8th registered.
Pfizer’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing abrocitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07848074Fondazione Policlinico Universitario Agostino Gemelli IRCCSAbrocitinib Dose Tapering in Patients With Atopic Dermatitis | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, from their registry updates:
Among Pfizer’s 58 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstrate the efficacy of PF 04965842 by showing improvement in disease severity in patients with moderate to severe AD as measured by the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) scores, and safety to support further clinical development of PF 04965842.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have the following atopic dermatitis criteria:
Exclusion Criteria:
Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated .
Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.
Within 1 week of first dose of study drug: Topical treatments that could affect atopic dermatitis; Herbal medications with unknown properties or known beneficial effects for AD.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg of PF-04965842 QD
Drug: PF-04965842
30 mg of PF-04965842 QD
Drug: PF-04965842
100 mg of PF-04965842 QD
Drug: PF-04965842
200 mg of PF-04965842 QD
Drug: PF-04965842
placebo QD
Drug: Placebo
10 mg of PF-04965842 QD for 12 weeks
30 mg of PF-04965842 QD for 12 weeks
100 mg of PF-04965842 QD for 12 weeks
200 mg of PF-04965842 QD for 12 weeks
Placebo QD for 12 weeks
Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 12
The IGA score quantifies the severity of participants' atopic dermatitis (AD). Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).
Time frame: Baseline and Week 12
Percent Change From Baseline in the Eczema Area and Severity Index (EASI) at Week 12
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
Time frame: Baseline and Week 12
Percentage of Participants Achieving the IGA for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12
The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).
Time frame: Baseline and all scheduled time points except Week 12, including Weeks 1, 2, 4, 6, 8, 13, 14, 16.
Percentage of Participants Achieving >=2 Points Improvement in the IGA From Baseline at All Scheduled Time Points
The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Percent Change From Baseline in the EASI Total Score at All Scheduled Time Points Except Week 12.
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
Time frame: Baseline and all scheduled time points except Week 12, including Weeks 1, 2, 4, 6, 8, 13, 14, 16
Percentage of Participants Achieving >=3 Points Improvement in the Pruritus Numerical Rating Scale (NRS) From Baseline at All Scheduled Time Points
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Percentage of Participants Achieving >=4 Points Improvement in the Pruritus NRS From Baseline at All Scheduled Time Points
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Time to Achieving >=3 Points Improvement in NRS
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
Time frame: Baseline till Week 16
Time to Achieving >=4 Points Improvement in NRS
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
Time frame: Baseline till Week 16
Percent Change From Baseline in the Pruritus NRS From Baseline at All Scheduled Time Points
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Change From Baseline in Pruritus NRS Score at All Scheduled Time Points
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Percentage of Participants Achieving a >=50% Improvement in the EASI Total Score (EASI50) at All Scheduled Time Points
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
Time frame: All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Percentage of Participants Achieving a >=75% Improvement in the EASI Total Score (EASI75) at All Scheduled Time Points
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
Time frame: All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Percentage of Participants Achieving a >=90% Improvement in the EASI Total Score (EASI90) at All Scheduled Time Points
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
Time frame: All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Change From Baseline in Affected BSA at All Scheduled Time Points
BSA Efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA Efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. Since the scalp, palms, and soles are excluded from the BSA (Efficacy) assessment, the maximum possible value is less than 100%.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) at All Scheduled Time Points
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Percent Change From Baseline in SCORAD at All Scheduled Time Points
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Percentage of Participants Achieving a >=50% Improvement in SCORAD (SCORAD50) From Baseline at All Scheduled Time Points
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Percentage of Participants Achieving a >=75% Improvement in SCORAD (SCORAD75) From Baseline at All Scheduled Time Points
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Number of Participants With Treatment-emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were events that occurred between the first dose of study drug and the subject's last visit (Week 16) that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline till Week 16
Number of Participants With Specific Clinical Laboratory Abnormalities (Anemia, Neutropenia, Thrombocytopenia, Lymphopenia, Lipid Profile, Liver Function Tests (LFTs)
Time frame: Baseline up to Week 16
Percentage of Participants With Patient Global Assessment (PtGA) of AD of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points
The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the Physician's Global Assessment was used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at All Scheduled Time Points
The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). It has been extensively used in clinical trials for AD. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 2-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
Change From Baseline in Patient Oriented Eczema Measure (POEM) at All Scheduled Time Points
The POEM is a 7-item patient reported outcome (PRO) measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
Change From Baseline in the Hospital and Anxiety Depression Scale (HADS) at All Scheduled Time Points
The HADS is a 14-item PRO measure used to detect states of anxiety and depression over the past week. The HADS was completed as per schedule of activities. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.
Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
| Milestone | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Started | 56 | 49 | 51 | 56 | 55 |
| Completed | 28 | 27 | 27 | 37 | 38 |
| Not completed | 28 | 22 | 24 | 19 | 17 |
| Withdrew: Adverse event | 9 | 8 | 8 | 12 | 8 |
| Withdrew: Lack of efficacy | 6 | 5 | 6 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Does not meet entrance criteria | 0 | 0 | 1 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 5 | 5 | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 6 | 4 | 4 | 3 | 4 |
| Withdrew: Other | 0 | 0 | 3 | 1 | 2 |
The IGA score quantifies the severity of participants' atopic dermatitis (AD). Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 12 | 6.3 ± 2.55 | 8.2 ± 2.32 | 12.3 ± 2.88 | 27.8 ± 5.07 | 44.5 ± 6.92 |
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
| percent change | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Percent Change From Baseline in the Eczema Area and Severity Index (EASI) at Week 12 | -35.22 ± 6.572 | -31.13 ± 7.090 | -40.73 ± 6.823 | -59.04 ± 6.212 | -82.57 ± 6.161 |
The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 0.0 | 2.1 | 2.0 | 1.8 | 3.7 |
| Week 2 | 3.6 | 6.1 | 6.0 | 3.6 | 11.5 |
| Week 4 | 1.8 | 8.2 | 8.0 | 16.4 | 40.7 |
| Week 6 | 14.5 | 14.3 | 14.0 | 12.7 | 40.7 |
| Week 8 | 5.5 | 8.2 | 12.0 | 16.4 | 41.5 |
| Week 13 | 10.0 | 20.7 | 12.9 | 23.7 | 26.7 |
| Week 14 | 18.8 | 10.7 | 3.4 | 12.5 | 15.9 |
| Week 16 | 10.7 | 23.1 | 7.4 | 13.9 | 18.4 |
The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 1.9 | 4.2 | 6.1 | 5.5 | 9.4 |
| Week 2 | 7.3 | 10.4 | 10.6 | 11.3 | 24.0 |
| Week 4 | 8.0 | 11.1 | 12.8 | 25.0 | 51.9 |
| Week 6 | 22.7 | 23.7 | 18.6 | 29.2 | 59.6 |
| Week 8 | 14.6 | 19.4 | 23.3 | 34.0 | 59.2 |
| Week 12 | 17.1 | 17.2 | 23.3 | 51.2 | 57.1 |
| Week 13 | 13.3 | 24.1 | 12.9 | 26.3 | 37.8 |
| Week 14 | 21.9 | 17.9 | 10.3 | 20.0 | 25.0 |
| Week 16 | 14.3 | 26.9 | 11.1 | 22.2 | 31.6 |
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
| Percent change | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | -12.28 ± 27.205 | -13.80 ± 26.526 | -14.85 ± 33.721 | -19.85 ± 30.379 | -41.26 ± 32.064 |
| Week 2 | -23.54 ± 33.348 | -14.79 ± 40.474 | -26.29 ± 33.298 | -38.26 ± 39.176 | -63.28 ± 25.754 |
| Week 4 | -24.58 ± 40.520 | -30.06 ± 40.852 | -32.81 ± 40.255 | -53.59 ± 35.274 | -78.16 ± 20.666 |
| Week 6 | -39.17 ± 39.299 | -35.18 ± 43.498 | -40.16 ± 43.849 | -54.16 ± 53.212 | -83.14 ± 17.267 |
| Week 8 | -36.69 ± 42.629 | -39.43 ± 46.270 | -36.83 ± 52.632 | -53.96 ± 53.689 | -84.48 ± 16.226 |
| Week 13 | -29.82 ± 50.404 | -34.11 ± 51.089 | -32.97 ± 45.223 | -51.23 ± 45.968 | -66.34 ± 34.951 |
| Week 14 | -35.51 ± 43.357 | -31.54 ± 62.829 | -26.25 ± 49.184 | -38.80 ± 49.085 | -57.15 ± 36.739 |
| Week 16 | -35.91 ± 47.713 | -45.24 ± 44.576 | -20.80 ± 47.915 | -27.66 ± 54.570 | -55.82 ± 32.833 |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Itching due to AD Day 2 | 4.0 | 6.7 | 17.0 | 14.8 | 17.0 |
| Itching due to AD Day 3 | 8.0 | 2.2 | 14.9 | 22.2 | 28.3 |
| Itching due to AD Day 4 | 2.0 | 2.2 | 21.3 | 22.2 | 34.6 |
| Itching due to AD Day 5 | 2.0 | 6.7 | 29.8 | 24.1 | 36.5 |
| Itching due to AD Day 6 | 10.0 | 8.9 | 25.5 | 24.1 | 40.4 |
| Itching due to AD Day 7 | 11.8 | 13.3 | 25.5 | 30.2 | 42.3 |
| Itching due to AD Day 8 | 10.0 | 13.3 | 25.0 | 43.6 | 51.0 |
| Itching due to AD Day 9 | 8.3 | 11.1 | 26.1 | 45.5 | 50.0 |
| Itching due to AD Day 10 | 8.2 | 11.1 | 34.0 | 43.6 | 55.8 |
| Itching due to AD Day 11 | 16.0 | 15.6 | 27.7 | 43.6 | 57.7 |
| Itching due to AD Day 12 | 22.0 | 17.8 | 38.3 | 49.1 | 60.8 |
| Itching due to AD Day 13 | 24.0 | 15.6 | 28.3 | 53.8 | 66.0 |
| Itching due to AD Day 14 | 22.4 | 19.0 | 26.7 | 48.1 | 67.3 |
| Itching due to AD Day 15 | 25.0 | 17.9 | 30.8 | 54.5 | 72.5 |
| Itching due to AD Day 29 | 32.7 | 31.1 | 37.8 | 60.0 | 74.5 |
| Itching due to AD Day 43 | 31.4 | 35.4 | 38.3 | 53.7 | 73.1 |
| Itching due to AD Day 57 | 28.8 | 31.9 | 38.3 | 54.5 | 72.0 |
| Itching due to AD Day 85 | 26.9 | 21.3 | 41.3 | 53.7 | 64.0 |
| Itching due to AD Day 99 | 33.3 | 25.9 | 33.3 | 47.5 | 41.5 |
| Itching due to AD Day 113 | 52.2 | 29.2 | 24.0 | 44.4 | 35.3 |
| Frequency of itching due to AD Day 2 | 6.0 | 8.9 | 19.1 | 22.2 | 26.4 |
| Frequency of itching due to AD Day 3 | 10.0 | 8.9 | 19.1 | 25.9 | 34.0 |
| Frequency of itching due to AD Day 4 | 8.0 | 4.4 | 23.4 | 25.9 | 48.1 |
| Frequency of itching due to AD Day 5 | 10.0 | 6.7 | 31.9 | 29.6 | 46.2 |
| Frequency of itching due to AD Day 6 | 14.0 | 8.9 | 27.7 | 33.3 | 57.7 |
| Frequency of itching due to AD Day 7 | 15.7 | 11.1 | 31.9 | 34.0 | 55.8 |
| Frequency of itching due to AD Day 8 | 16.0 | 11.1 | 29.2 | 45.5 | 60.8 |
| Frequency of itching due to AD Day 9 | 14.6 | 13.3 | 30.4 | 45.5 | 55.8 |
| Frequency of itching due to AD Day 10 | 14.3 | 13.3 | 36.2 | 45.5 | 65.4 |
| Frequency of itching due to AD Day 11 | 20.0 | 15.6 | 36.2 | 45.5 | 63.5 |
| Frequency of itching due to AD Day 12 | 18.0 | 17.8 | 38.3 | 50.9 | 60.8 |
| Frequency of itching due to AD Day 13 | 20.0 | 20.0 | 30.4 | 51.9 | 70.0 |
| Frequency of itching due to AD Day 14 | 24.5 | 23.8 | 33.3 | 48.1 | 71.4 |
| Frequency of itching due to AD Day 15 | 30.0 | 20.5 | 38.5 | 52.3 | 72.5 |
| Frequency of itching due to AD Day 29 | 28.8 | 28.9 | 40.0 | 60.0 | 74.5 |
| Frequency of itching due to AD Day 43 | 23.5 | 35.4 | 38.3 | 57.4 | 75.0 |
| Frequency of itching due to AD Day 57 | 26.9 | 29.8 | 38.3 | 54.5 | 74.0 |
| Frequency of itching due to AD Day 85 | 25.0 | 25.5 | 34.8 | 53.7 | 70.0 |
| Frequency of itching due to AD Day 99 | 30.0 | 22.2 | 37.0 | 47.5 | 39.0 |
| Frequency of itching due to AD Day 113 | 47.8 | 25.0 | 20.0 | 47.2 | 38.2 |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Itching due to AD Day 2 | 2.0 | 2.2 | 6.5 | 10.0 | 15.2 |
| Itching due to AD Day 3 | 0.0 | 2.2 | 13.0 | 14.0 | 21.7 |
| Itching due to AD Day 4 | 0.0 | 0.0 | 17.4 | 14.0 | 28.9 |
| Itching due to AD Day 5 | 2.0 | 2.2 | 19.6 | 20.0 | 26.7 |
| Itching due to AD Day 6 | 6.1 | 2.2 | 17.4 | 24.0 | 35.6 |
| Itching due to AD Day 7 | 8.0 | 8.9 | 19.6 | 20.4 | 37.8 |
| Itching due to AD Day 8 | 6.1 | 4.4 | 14.9 | 29.4 | 52.3 |
| Itching due to AD Day 9 | 2.1 | 6.7 | 20.0 | 27.5 | 51.1 |
| Itching due to AD Day 10 | 4.2 | 6.7 | 21.7 | 29.4 | 44.4 |
| Itching due to AD Day 11 | 8.2 | 13.3 | 19.6 | 29.4 | 44.4 |
| Itching due to AD Day 12 | 10.2 | 11.1 | 23.9 | 35.3 | 51.1 |
| Itching due to AD Day 13 | 14.3 | 6.7 | 20.0 | 38.8 | 61.4 |
| Itching due to AD Day 14 | 10.4 | 14.3 | 25.0 | 41.7 | 59.1 |
| Itching due to AD Day 15 | 15.0 | 7.9 | 31.6 | 41.9 | 70.3 |
| Itching due to AD Day 29 | 17.6 | 13.6 | 25.0 | 52.9 | 68.9 |
| Itching due to AD Day 43 | 20.0 | 22.2 | 23.9 | 50.0 | 71.7 |
| Itching due to AD Day 57 | 17.6 | 22.7 | 26.1 | 52.9 | 72.7 |
| Itching due to AD Day 85 | 25.5 | 22.7 | 33.3 | 50.0 | 63.6 |
| Itching due to AD Day 99 | 27.6 | 25.9 | 23.1 | 38.5 | 37.1 |
| Itching due to AD Day 113 | 43.5 | 20.8 | 16.7 | 34.3 | 31.0 |
| Frequency of itching due to AD Day 2 | 2.1 | 0.0 | 7.1 | 11.5 | 18.8 |
| Frequency of itching due to AD Day 3 | 6.4 | 2.2 | 11.9 | 13.5 | 22.9 |
| Frequency of itching due to AD Day 4 | 2.1 | 0.0 | 19.0 | 21.2 | 36.2 |
| Frequency of itching due to AD Day 5 | 4.3 | 4.4 | 23.8 | 25.0 | 38.3 |
| Frequency of itching due to AD Day 6 | 10.6 | 6.7 | 26.2 | 25.0 | 44.7 |
| Frequency of itching due to AD Day 7 | 10.4 | 4.4 | 19.0 | 30.0 | 51.1 |
| Frequency of itching due to AD Day 8 | 8.5 | 2.2 | 23.3 | 36.5 | 54.3 |
| Frequency of itching due to AD Day 9 | 6.7 | 6.7 | 26.8 | 36.5 | 48.9 |
| Frequency of itching due to AD Day 10 | 6.5 | 8.9 | 31.0 | 28.8 | 51.1 |
| Frequency of itching due to AD Day 11 | 10.6 | 15.6 | 23.8 | 32.7 | 55.3 |
| Frequency of itching due to AD Day 12 | 12.8 | 13.3 | 26.2 | 34.6 | 54.3 |
| Frequency of itching due to AD Day 13 | 17.0 | 15.6 | 29.3 | 32.0 | 66.7 |
| Frequency of itching due to AD Day 14 | 19.6 | 16.7 | 30.0 | 34.7 | 66.7 |
| Frequency of itching due to AD Day 15 | 20.0 | 15.8 | 35.3 | 36.4 | 71.1 |
| Frequency of itching due to AD Day 29 | 16.3 | 15.9 | 35.0 | 51.9 | 66.0 |
| Frequency of itching due to AD Day 43 | 12.5 | 24.4 | 28.6 | 58.8 | 72.9 |
| Frequency of itching due to AD Day 57 | 16.3 | 20.5 | 33.3 | 53.8 | 73.9 |
| Frequency of itching due to AD Day 85 | 24.5 | 25.0 | 28.6 | 47.1 | 69.6 |
| Frequency of itching due to AD Day 99 | 20.7 | 18.5 | 16.7 | 39.5 | 32.4 |
| Frequency of itching due to AD Day 113 | 34.8 | 20.8 | 22.7 | 29.4 | 26.7 |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
| day | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Itching due to AD | 30.0 (15.0 to 56.0) | 43.0 (29.0 to 57.0) | 12.0 (8.0 to 30.0) | 9.0 (7.0 to 14.0) | 7.0 (5.0 to 11.0) |
| Frequency of itching due to AD | 29.0 (13.0 to 57.0) | 43.0 (29.0 to 85.0) | 13.0 (7.0 to 43.0) | 8.0 (4.0 to 10.0) | 4.0 (4.0 to 6.0) |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
| day | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Itching due to atopic dermatitis | 78.0 (56.0 to NA) | NA (47.0 to NA) | 43.0 (15.0 to 85.0) | 14.0 (10.0 to 29.0) | 10.0 (7.0 to 13.0) |
| Frequency of itching due to atopic dermatitis | 59.0 (30.0 to NA) | NA (56.0 to NA) | 29.0 (12.0 to 98.0) | 14.0 (8.0 to 29.0) | 7.0 (5.0 to 9.0) |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
| percent change | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Itching due to AD Day 2 | 0.56 ± 19.298 | -1.51 ± 19.857 | -9.39 ± 23.528 | -10.06 ± 25.930 | -6.79 ± 47.751 |
| Itching due to AD Day 3 | -1.32 ± 22.630 | 2.48 ± 21.994 | -8.22 ± 33.257 | -15.32 ± 27.874 | -16.72 ± 40.055 |
| Itching due to AD Day 4 | -1.98 ± 22.326 | 0.23 ± 17.314 | -12.18 ± 33.385 | -17.62 ± 25.747 | -25.80 ± 38.557 |
| Itching due to AD Day 5 | -2.98 ± 22.385 | -2.37 ± 20.174 | -18.92 ± 31.846 | -20.48 ± 27.983 | -30.91 ± 34.215 |
| Itching due to AD Day 6 | -1.52 ± 25.690 | -5.70 ± 23.478 | -16.70 ± 33.407 | -21.58 ± 27.842 | -34.02 ± 35.532 |
| Itching due to AD Day 7 | -4.18 ± 30.531 | -4.59 ± 28.248 | -18.07 ± 33.640 | -23.02 ± 33.524 | -38.17 ± 35.428 |
| Itching due to AD Day 8 | -0.35 ± 34.144 | -5.69 ± 25.576 | -17.87 ± 34.789 | -32.36 ± 30.610 | -43.13 ± 38.684 |
| Itching due to AD Day 9 | -2.56 ± 30.688 | -8.61 ± 27.803 | -22.74 ± 33.667 | -31.82 ± 30.951 | -39.37 ± 41.055 |
| Itching due to AD Day 10 | -3.32 ± 29.885 | -5.97 ± 29.093 | -22.90 ± 41.573 | -31.93 ± 27.094 | -39.60 ± 56.607 |
| Itching due to AD Day 11 | -7.81 ± 30.201 | -5.94 ± 31.028 | -16.76 ± 49.412 | -33.13 ± 27.902 | -42.50 ± 51.621 |
| Itching due to AD Day 12 | -11.12 ± 30.087 | -6.65 ± 32.617 | -27.84 ± 33.416 | -33.30 ± 34.252 | -46.40 ± 46.241 |
| Itching due to AD Day 13 | -15.16 ± 29.759 | -7.43 ± 27.374 | -24.56 ± 30.086 | -35.89 ± 35.651 | -49.77 ± 48.426 |
| Itching due to AD Day 14 | -13.61 ± 30.153 | -8.84 ± 29.474 | -26.70 ± 29.805 | -36.57 ± 27.552 | -55.45 ± 34.331 |
| Itching due to AD Day 15 | -17.24 ± 30.755 | -7.28 ± 28.058 | -25.09 ± 37.815 | -35.41 ± 29.140 | -59.00 ± 39.804 |
| Itching due to AD Day 29 | -19.43 ± 35.575 | -16.63 ± 34.554 | -28.41 ± 36.183 | -46.62 ± 40.090 | -68.09 ± 31.214 |
| Itching due to AD Day 43 | -26.55 ± 36.418 | -27.15 ± 39.550 | -31.14 ± 39.090 | -49.49 ± 46.279 | -67.80 ± 36.372 |
| Itching due to AD Day 57 | -25.54 ± 39.577 | -21.60 ± 44.446 | -29.60 ± 39.606 | -54.11 ± 36.374 | -70.13 ± 36.338 |
| Itching due to AD Day 85 | -30.10 ± 42.697 | -22.47 ± 48.291 | -30.39 ± 47.772 | -56.51 ± 41.955 | -53.66 ± 109.454 |
| Itching due to AD Day 99 | -19.24 ± 43.251 | -15.94 ± 42.332 | -11.46 ± 39.959 | -32.68 ± 34.789 | 5.61 ± 139.223 |
| Itching due to AD Day 113 | -31.99 ± 45.929 | -14.07 ± 47.186 | -14.34 ± 29.756 | -28.47 ± 41.027 | 24.61 ± 190.848 |
| Frequency of itching due to AD Day 2 | 6.72 ± 45.759 | -6.67 ± 19.016 | -10.14 ± 28.184 | -17.93 ± 20.967 | -10.52 ± 79.180 |
| Frequency of itching due to AD Day 3 | 2.59 ± 45.541 | 0.30 ± 24.330 | -3.96 ± 49.425 | -19.98 ± 22.910 | -16.46 ± 67.794 |
| Frequency of itching due to AD Day 4 | 3.73 ± 37.683 | -3.25 ± 15.230 | -9.39 ± 39.225 | -20.71 ± 24.391 | -28.27 ± 47.925 |
| Frequency of itching due to AD Day 5 | -0.70 ± 34.834 | -3.73 ± 23.125 | -17.72 ± 38.967 | -23.69 ± 24.954 | -35.45 ± 37.436 |
| Frequency of itching due to AD Day 6 | 4.04 ± 52.799 | -5.76 ± 24.623 | -14.84 ± 38.256 | -26.47 ± 27.218 | -44.31 ± 36.476 |
| Frequency of itching due to AD Day 7 | -2.25 ± 37.193 | -3.56 ± 25.414 | -17.05 ± 40.108 | -27.80 ± 32.466 | -40.19 ± 39.702 |
| Frequency of itching due to AD Day 8 | 1.22 ± 38.544 | -3.90 ± 25.515 | -19.05 ± 36.488 | -35.44 ± 29.791 | -46.26 ± 43.491 |
| Frequency of itching due to AD Day 9 | 1.08 ± 58.633 | -8.79 ± 26.589 | -17.58 ± 42.054 | -35.17 ± 29.637 | -44.29 ± 43.238 |
| Frequency of itching due to AD Day 10 | -3.47 ± 53.518 | -5.41 ± 32.491 | -19.84 ± 47.884 | -33.23 ± 26.950 | -49.78 ± 37.349 |
| Frequency of itching due to AD Day 11 | -6.24 ± 49.163 | -5.88 ± 32.750 | -18.73 ± 42.599 | -34.93 ± 27.181 | -51.62 ± 37.385 |
| Frequency of itching due to AD Day 12 | -8.41 ± 49.918 | -5.65 ± 36.637 | -25.00 ± 31.695 | -36.55 ± 27.281 | -51.92 ± 40.010 |
| Frequency of itching due to AD Day 13 | -13.45 ± 40.159 | -10.46 ± 31.103 | -24.73 ± 31.960 | -35.75 ± 32.757 | -53.17 ± 40.695 |
| Frequency of itching due to AD Day 14 | -10.26 ± 46.126 | -13.86 ± 32.390 | -27.70 ± 30.476 | -38.28 ± 27.724 | -57.50 ± 39.073 |
| Frequency of itching due to AD Day 15 | -18.78 ± 34.923 | -11.34 ± 28.494 | -26.88 ± 38.846 | -38.87 ± 29.184 | -60.99 ± 32.840 |
| Frequency of itching due to AD Day 29 | -16.05 ± 39.630 | -17.15 ± 33.432 | -28.55 ± 43.421 | -49.94 ± 36.649 | -67.84 ± 29.918 |
| Frequency of itching due to AD Day 43 | -24.51 ± 30.798 | -32.19 ± 37.806 | -26.48 ± 46.793 | -53.95 ± 41.772 | -69.24 ± 38.370 |
| Frequency of itching due to AD Day 57 | -24.94 ± 35.662 | -23.28 ± 44.257 | -27.91 ± 39.142 | -55.39 ± 35.447 | -73.50 ± 30.583 |
| Frequency of itching due to AD Day 85 | -29.81 ± 44.035 | -25.76 ± 43.273 | -32.28 ± 38.817 | -54.51 ± 43.354 | -54.54 ± 120.723 |
| Frequency of itching due to AD Day 99 | -17.46 ± 43.552 | -20.21 ± 36.947 | -3.36 ± 52.153 | -13.57 ± 123.800 | 2.12 ± 144.572 |
| Frequency of itching due to AD Day 113 | -28.95 ± 46.896 | -16.22 ± 38.055 | -5.65 ± 51.132 | -12.62 ± 113.423 | 27.77 ± 203.937 |
The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).
| units on a scale | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Itching due to AD Day 2 | -0.08 ± 1.307 | -0.20 ± 1.217 | -0.83 ± 1.672 | -0.85 ± 1.607 | -1.00 ± 2.433 |
| Itching due to AD Day 3 | -0.22 ± 1.418 | 0.02 ± 1.357 | -0.85 ± 2.095 | -1.21 ± 1.702 | -1.48 ± 2.493 |
| Itching due to AD Day 4 | -0.22 ± 1.389 | -0.09 ± 1.117 | -1.09 ± 2.263 | -1.26 ± 1.862 | -2.12 ± 2.590 |
| Itching due to AD Day 5 | -0.32 ± 1.406 | -0.27 ± 1.264 | -1.55 ± 2.348 | -1.58 ± 1.865 | -2.35 ± 2.583 |
| Itching due to AD Day 6 | -0.28 ± 1.727 | -0.55 ± 1.405 | -1.47 ± 2.492 | -1.49 ± 2.317 | -2.53 ± 2.648 |
| Itching due to AD Day 7 | -0.53 ± 2.023 | -0.52 ± 1.745 | -1.51 ± 2.422 | -1.75 ± 2.159 | -2.77 ± 2.795 |
| Itching due to AD Day 8 | -0.30 ± 2.215 | -0.56 ± 1.560 | -1.65 ± 2.514 | -2.39 ± 2.294 | -3.22 ± 3.039 |
| Itching due to AD Day 9 | -0.38 ± 2.080 | -0.75 ± 1.844 | -1.95 ± 2.527 | -2.40 ± 2.154 | -3.18 ± 2.988 |
| Itching due to AD Day 10 | -0.43 ± 1.947 | -0.61 ± 1.967 | -2.09 ± 2.698 | -2.21 ± 2.412 | -3.38 ± 2.975 |
| Itching due to AD Day 11 | -0.73 ± 1.955 | -0.61 ± 2.148 | -1.72 ± 2.462 | -2.33 ± 2.415 | -3.40 ± 3.071 |
| Itching due to AD Day 12 | -0.92 ± 1.988 | -0.73 ± 2.245 | -2.28 ± 2.271 | -2.46 ± 2.578 | -3.63 ± 3.154 |
| Itching due to AD Day 13 | -1.21 ± 1.989 | -0.68 ± 1.801 | -1.98 ± 2.268 | -2.84 ± 2.164 | -3.88 ± 3.085 |
| Itching due to AD Day 14 | -1.11 ± 2.003 | -0.78 ± 2.104 | -2.10 ± 2.211 | -2.53 ± 2.567 | -4.06 ± 2.793 |
| Itching due to AD Day 15 | -1.39 ± 2.034 | -0.69 ± 1.937 | -2.06 ± 2.508 | -2.79 ± 2.290 | -4.37 ± 2.696 |
| Itching due to AD Day 29 | -1.63 ± 2.453 | -1.34 ± 2.383 | -2.17 ± 2.519 | -3.58 ± 3.322 | -5.00 ± 2.880 |
| Itching due to AD Day 43 | -1.93 ± 2.325 | -2.24 ± 2.929 | -2.50 ± 2.562 | -3.77 ± 3.778 | -5.02 ± 3.172 |
| Itching due to AD Day 57 | -1.84 ± 2.594 | -1.97 ± 3.398 | -2.55 ± 2.943 | -4.00 ± 3.336 | -5.26 ± 3.130 |
| Itching due to AD Day 85 | -2.26 ± 3.081 | -2.13 ± 3.711 | -2.68 ± 2.749 | -4.21 ± 3.529 | -4.84 ± 3.785 |
| Itching due to AD Day 99 | -1.57 ± 3.025 | -1.48 ± 2.992 | -1.37 ± 2.452 | -2.28 ± 2.900 | -1.90 ± 3.767 |
| Itching due to AD Day 113 | -2.43 ± 3.259 | -1.38 ± 3.201 | -1.32 ± 2.410 | -2.03 ± 3.185 | -1.50 ± 3.736 |
| Frequency of itching due to AD Day 2 | -0.06 ± 1.754 | -0.44 ± 1.198 | -0.94 ± 1.737 | -1.35 ± 1.556 | -1.60 ± 2.345 |
| Frequency of itching due to AD Day 3 | -0.38 ± 1.894 | -0.16 ± 1.461 | -0.79 ± 2.331 | -1.49 ± 1.694 | -1.92 ± 2.300 |
| Frequency of itching due to AD Day 4 | -0.20 ± 1.738 | -0.32 ± 1.073 | -1.02 ± 2.162 | -1.40 ± 2.069 | -2.47 ± 2.533 |
| Frequency of itching due to AD Day 5 | -0.42 ± 1.727 | -0.43 ± 1.516 | -1.49 ± 2.349 | -1.75 ± 1.828 | -2.73 ± 2.515 |
| Frequency of itching due to AD Day 6 | -0.40 ± 2.250 | -0.55 ± 1.606 | -1.40 ± 2.402 | -1.77 ± 2.326 | -3.24 ± 2.446 |
| Frequency of itching due to AD Day 7 | -0.63 ± 2.181 | -0.43 ± 1.676 | -1.53 ± 2.466 | -2.04 ± 2.214 | -3.15 ± 2.739 |
| Frequency of itching due to AD Day 8 | -0.42 ± 2.205 | -0.40 ± 1.679 | -1.74 ± 2.542 | -2.59 ± 2.278 | -3.69 ± 2.808 |
| Frequency of itching due to AD Day 9 | -0.54 ± 2.240 | -0.75 ± 2.036 | -1.74 ± 2.567 | -2.62 ± 2.268 | -3.54 ± 3.018 |
| Frequency of itching due to AD Day 10 | -0.80 ± 2.198 | -0.64 ± 2.200 | -1.84 ± 2.760 | -2.33 ± 2.565 | -3.68 ± 2.591 |
| Frequency of itching due to AD Day 11 | -0.96 ± 2.336 | -0.68 ± 2.380 | -1.79 ± 2.541 | -2.46 ± 2.540 | -3.74 ± 2.633 |
| Frequency of itching due to AD Day 12 | -1.06 ± 2.322 | -0.66 ± 2.411 | -2.00 ± 2.182 | -2.54 ± 2.509 | -3.84 ± 2.932 |
| Frequency of itching due to AD Day 13 | -1.33 ± 2.337 | -0.91 ± 2.133 | -1.90 ± 2.195 | -2.78 ± 2.275 | -4.08 ± 2.952 |
| Frequency of itching due to AD Day 14 | -1.17 ± 2.417 | -1.10 ± 2.417 | -2.00 ± 2.225 | -2.63 ± 2.620 | -4.28 ± 2.841 |
| Frequency of itching due to AD Day 15 | -1.50 ± 2.322 | -0.97 ± 2.135 | -2.17 ± 2.407 | -3.02 ± 2.464 | -4.50 ± 2.648 |
| Frequency of itching due to AD Day 29 | -1.46 ± 2.518 | -1.34 ± 2.425 | -2.22 ± 2.761 | -3.77 ± 3.317 | -5.06 ± 2.817 |
| Frequency of itching due to AD Day 43 | -1.70 ± 1.990 | -2.51 ± 3.061 | -2.28 ± 2.953 | -4.02 ± 3.796 | -5.30 ± 2.957 |
| Frequency of itching due to AD Day 57 | -1.74 ± 2.298 | -2.00 ± 3.499 | -2.45 ± 2.943 | -4.02 ± 3.467 | -5.59 ± 3.037 |
| Frequency of itching due to AD Day 85 | -2.23 ± 3.209 | -2.33 ± 3.575 | -2.61 ± 2.692 | -4.09 ± 3.663 | -5.14 ± 3.645 |
| Frequency of itching due to AD Day 99 | -1.30 ± 2.781 | -1.56 ± 2.736 | -0.93 ± 2.526 | -2.03 ± 3.378 | -2.15 ± 3.909 |
| Frequency of itching due to AD Day 113 | -2.00 ± 2.970 | -1.42 ± 3.035 | -1.04 ± 2.557 | -1.81 ± 3.188 | -1.50 ± 3.816 |
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 9.3 | 8.3 | 14.0 | 12.7 | 40.7 |
| Week 2 | 27.3 | 16.3 | 24.0 | 36.4 | 65.4 |
| Week 4 | 27.3 | 30.6 | 36.0 | 58.2 | 85.2 |
| Week 6 | 36.4 | 30.6 | 40.0 | 60.0 | 90.7 |
| Week 8 | 30.9 | 36.7 | 40.0 | 60.0 | 90.6 |
| Week 12 | 26.9 | 26.1 | 33.3 | 55.6 | 79.2 |
| Week 13 | 43.3 | 41.4 | 45.2 | 55.3 | 75.6 |
| Week 14 | 37.5 | 42.9 | 37.9 | 50.0 | 65.9 |
| Week 16 | 42.9 | 42.3 | 33.3 | 41.7 | 68.4 |
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 3.7 | 2.1 | 6.0 | 3.6 | 16.7 |
| Week 2 | 5.5 | 12.2 | 6.0 | 12.7 | 36.5 |
| Week 4 | 10.9 | 18.4 | 20.0 | 27.3 | 57.4 |
| Week 6 | 16.4 | 18.4 | 18.0 | 38.2 | 68.5 |
| Week 8 | 20.0 | 22.4 | 22.0 | 40.0 | 73.6 |
| Week 12 | 15.4 | 17.4 | 13.3 | 40.7 | 64.6 |
| Week 13 | 26.7 | 27.6 | 12.9 | 36.8 | 55.6 |
| Week 14 | 31.3 | 25.0 | 6.9 | 35.0 | 45.5 |
| Week 16 | 32.1 | 38.5 | 3.7 | 25.0 | 36.8 |
The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 0.0 | 2.1 | 4.0 | 0.0 | 7.4 |
| Week 2 | 0.0 | 6.1 | 4.0 | 5.5 | 19.2 |
| Week 4 | 1.8 | 8.2 | 8.0 | 10.9 | 38.9 |
| Week 6 | 7.3 | 14.3 | 14.0 | 16.4 | 44.4 |
| Week 8 | 5.5 | 12.2 | 8.0 | 23.6 | 43.4 |
| Week 12 | 9.6 | 10.9 | 0.0 | 25.9 | 52.1 |
| Week 13 | 10.0 | 13.8 | 3.2 | 23.7 | 31.1 |
| Week 14 | 15.6 | 14.3 | 0.0 | 17.5 | 18.2 |
| Week 16 | 14.3 | 23.1 | 3.7 | 8.3 | 10.5 |
BSA Efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA Efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. Since the scalp, palms, and soles are excluded from the BSA (Efficacy) assessment, the maximum possible value is less than 100%.
| percentage of BSA | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | -0.06 ± 6.699 | -3.76 ± 13.940 | -2.45 ± 7.017 | -4.63 ± 12.144 | -10.86 ± 15.690 |
| Week 2 | -5.43 ± 10.030 | -4.84 ± 16.179 | -6.51 ± 10.485 | -10.80 ± 16.432 | -21.30 ± 19.285 |
| Week 4 | -6.34 ± 16.138 | -8.93 ± 15.960 | -9.59 ± 14.845 | -17.77 ± 19.956 | -28.55 ± 20.447 |
| Week 6 | -10.79 ± 16.413 | -11.80 ± 22.324 | -10.71 ± 15.007 | -18.80 ± 23.387 | -30.51 ± 20.853 |
| Week 8 | -9.71 ± 17.837 | -12.98 ± 25.552 | -10.79 ± 19.259 | -19.41 ± 23.596 | -29.98 ± 20.864 |
| Week 12 | -13.82 ± 22.348 | -11.59 ± 27.112 | -9.37 ± 18.783 | -22.21 ± 22.199 | -27.72 ± 18.361 |
| Week 13 | -7.90 ± 18.233 | -11.07 ± 25.457 | -7.79 ± 17.469 | -17.88 ± 20.905 | -22.61 ± 22.390 |
| Week 14 | -8.97 ± 16.223 | -10.46 ± 26.130 | -6.33 ± 17.404 | -12.75 ± 22.492 | -16.35 ± 18.931 |
| Week 16 | -8.09 ± 15.797 | -14.64 ± 20.948 | -3.52 ± 20.967 | -5.55 ± 21.079 | -17.88 ± 17.059 |
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
| units on a scale | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | -7.910 ± 12.4625 | -5.000 ± 13.3310 | -8.388 ± 14.6316 | -12.024 ± 12.4053 | -21.326 ± 15.8867 |
| Week 2 | -10.905 ± 15.4157 | -8.795 ± 16.3883 | -13.266 ± 14.5268 | -20.286 ± 15.2402 | -32.152 ± 14.4354 |
| Week 4 | -14.555 ± 16.6414 | -14.116 ± 19.1643 | -15.496 ± 16.4795 | -28.058 ± 16.6775 | -39.567 ± 14.7328 |
| Week 6 | -19.527 ± 16.7869 | -16.667 ± 21.8577 | -19.930 ± 17.5966 | -29.729 ± 21.6156 | -41.458 ± 14.3943 |
| Week 8 | -19.052 ± 18.5735 | -18.853 ± 21.7947 | -19.534 ± 18.7098 | -30.148 ± 20.7887 | -42.604 ± 13.9771 |
| Week 12 | -18.647 ± 20.0191 | -17.986 ± 23.1948 | -21.211 ± 17.6774 | -33.145 ± 21.4221 | -41.384 ± 15.4359 |
| Week 13 | -16.603 ± 21.3850 | -16.895 ± 22.1132 | -15.023 ± 16.1573 | -24.261 ± 19.4912 | -29.884 ± 19.1501 |
| Week 14 | -17.987 ± 22.0893 | -15.842 ± 19.5000 | -12.768 ± 13.6914 | -20.211 ± 20.2920 | -21.292 ± 17.7775 |
| Week 16 | -19.408 ± 22.1744 | -18.925 ± 21.5459 | -12.716 ± 15.9390 | -17.753 ± 19.1842 | -21.024 ± 18.1576 |
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
| percent change | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | -11.547 ± 19.7128 | -7.287 ± 20.6403 | -13.068 ± 21.0746 | -19.185 ± 20.0094 | -34.660 ± 25.0837 |
| Week 2 | -16.488 ± 23.0011 | -12.980 ± 25.5198 | -20.613 ± 21.0283 | -31.025 ± 23.9881 | -51.384 ± 21.3581 |
| Week 4 | -22.476 ± 26.5163 | -20.751 ± 29.0846 | -24.866 ± 25.3755 | -43.846 ± 26.2001 | -63.970 ± 21.6701 |
| Week 6 | -30.789 ± 27.9424 | -25.851 ± 34.2950 | -31.276 ± 29.6517 | -45.270 ± 34.3893 | -66.971 ± 22.4343 |
| Week 8 | -29.624 ± 30.5625 | -28.599 ± 33.1460 | -30.480 ± 29.4742 | -46.187 ± 32.7984 | -69.736 ± 21.4403 |
| Week 12 | -29.379 ± 31.9081 | -27.607 ± 36.5015 | -32.535 ± 25.2711 | -51.624 ± 33.0106 | -68.537 ± 24.2392 |
| Week 13 | -26.794 ± 34.3384 | -26.905 ± 34.1879 | -24.232 ± 26.2461 | -38.193 ± 32.3458 | -48.428 ± 30.1133 |
| Week 14 | -29.393 ± 36.6642 | -25.511 ± 31.1985 | -20.072 ± 21.7399 | -31.521 ± 34.1268 | -36.519 ± 28.5404 |
| Week 16 | -31.972 ± 36.5058 | -30.135 ± 34.2361 | -19.794 ± 25.0550 | -29.130 ± 33.1868 | -34.995 ± 27.4996 |
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 3.7 | 2.1 | 6.0 | 7.3 | 29.6 |
| Week 2 | 5.5 | 10.2 | 10.0 | 18.2 | 55.8 |
| Week 4 | 20.0 | 12.2 | 16.0 | 43.6 | 75.9 |
| Week 6 | 21.8 | 16.3 | 26.0 | 45.5 | 74.1 |
| Week 8 | 23.6 | 22.4 | 30.0 | 43.6 | 73.6 |
| Week 12 | 19.2 | 13.0 | 15.6 | 50.0 | 72.9 |
| Week 13 | 26.7 | 20.7 | 16.1 | 34.2 | 48.9 |
| Week 14 | 31.3 | 17.9 | 3.4 | 32.5 | 36.4 |
| Week 16 | 39.3 | 30.8 | 14.8 | 25.0 | 34.2 |
SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 0.0 | 2.1 | 2.0 | 1.8 | 3.7 |
| Week 2 | 0.0 | 2.0 | 2.0 | 3.6 | 11.5 |
| Week 4 | 1.8 | 4.1 | 4.0 | 14.5 | 27.8 |
| Week 6 | 5.5 | 12.2 | 4.0 | 20.0 | 37.0 |
| Week 8 | 3.6 | 6.1 | 2.0 | 16.4 | 35.8 |
| Week 12 | 3.8 | 10.9 | 0.0 | 18.5 | 37.5 |
| Week 13 | 13.3 | 10.3 | 0.0 | 18.4 | 15.6 |
| Week 14 | 15.6 | 7.1 | 0.0 | 12.5 | 11.4 |
| Week 16 | 14.3 | 11.5 | 0.0 | 11.1 | 2.6 |
An AE was any untoward medical occurrence in a subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were events that occurred between the first dose of study drug and the subject's last visit (Week 16) that were absent before treatment or that worsened relative to pretreatment state.
| participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (AEs) | 32 | 34 | 34 | 43 | 41 |
| participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| AEs of anemia | 0 | 0 | 0 | 0 | 0 |
| AEs of neutropenia | 0 | 0 | 0 | 0 | 1 |
| AEs of thrombocytopenia | 0 | 0 | 0 | 0 | 1 |
| AEs of lymphopenia | 0 | 0 | 0 | 0 | 0 |
| AEs of lipid profile | 0 | 0 | 0 | 0 | 0 |
| AEs of liver function tests | 0 | 0 | 0 | 0 | 0 |
The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the Physician's Global Assessment was used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.
| percentage of participants | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | 0.0 | 2.1 | 4.1 | 1.9 | 16.7 |
| Week 2 | 5.6 | 0.0 | 6.1 | 16.7 | 32.7 |
| Week 4 | 3.8 | 6.1 | 8.2 | 22.2 | 54.7 |
| Week 6 | 3.8 | 10.2 | 8.2 | 22.2 | 51.9 |
| Week 8 | 1.9 | 6.1 | 6.1 | 24.1 | 56.6 |
| Week 12 | 7.4 | 12.5 | 0.0 | 25.9 | 51.9 |
| Week 14 | 3.2 | 10.3 | 0.0 | 15.8 | 15.6 |
| Week 16 | 11.1 | 7.7 | 0.0 | 11.8 | 10.5 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). It has been extensively used in clinical trials for AD. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 2-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality.
| units on a scale | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | -1.4 ± 6.04 | -1.4 ± 5.66 | -3.4 ± 6.28 | -5.1 ± 5.40 | -6.3 ± 5.55 |
| Week 2 | -2.3 ± 5.42 | -1.9 ± 6.58 | -5.0 ± 5.55 | -7.5 ± 6.39 | -8.6 ± 6.46 |
| Week 4 | -2.6 ± 6.77 | -3.7 ± 7.33 | -4.7 ± 5.62 | -8.2 ± 7.48 | -9.7 ± 6.82 |
| Week 6 | -4.2 ± 6.01 | -4.6 ± 7.30 | -4.1 ± 7.75 | -9.1 ± 6.75 | -10.2 ± 6.72 |
| Week 8 | -3.7 ± 7.67 | -5.6 ± 8.44 | -4.8 ± 8.52 | -9.2 ± 7.95 | -9.8 ± 7.10 |
| Week 12 | -4.6 ± 8.49 | -4.5 ± 8.90 | -5.2 ± 7.30 | -9.8 ± 8.18 | -9.5 ± 7.28 |
| Week 14 | -3.1 ± 8.24 | -3.9 ± 7.62 | -3.6 ± 6.60 | -6.2 ± 7.87 | -4.4 ± 8.78 |
| Week 16 | -4.5 ± 7.95 | -4.5 ± 7.14 | -3.5 ± 7.17 | -4.6 ± 7.62 | -3.6 ± 7.39 |
The POEM is a 7-item patient reported outcome (PRO) measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.
| units on a scale | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Week 1 | -1.1 ± 3.59 | -0.6 ± 4.17 | -2.1 ± 5.83 | -3.9 ± 4.67 | -9.2 ± 5.77 |
| Week 2 | -2.2 ± 4.20 | -1.9 ± 6.13 | -4.1 ± 6.04 | -7.2 ± 6.79 | -11.9 ± 5.95 |
| Week 4 | -2.2 ± 6.05 | -3.6 ± 6.35 | -4.3 ± 5.69 | -8.7 ± 8.30 | -14.6 ± 6.20 |
| Week 6 | -3.5 ± 5.24 | -4.3 ± 7.63 | -3.9 ± 7.43 | -10.4 ± 8.17 | -15.0 ± 5.92 |
| Week 8 | -2.3 ± 5.91 | -4.3 ± 8.94 | -5.4 ± 8.05 | -10.6 ± 8.47 | -15.2 ± 6.15 |
| Week 12 | -3.8 ± 8.21 | -4.7 ± 8.83 | -5.3 ± 7.60 | -11.4 ± 8.08 | -15.1 ± 6.99 |
| Week 14 | -2.2 ± 6.45 | -3.9 ± 8.04 | -2.7 ± 6.05 | -6.3 ± 7.12 | -6.2 ± 6.97 |
| Week 16 | -3.0 ± 7.76 | -3.0 ± 7.67 | -2.2 ± 6.80 | -4.3 ± 6.20 | -5.9 ± 5.93 |
The HADS is a 14-item PRO measure used to detect states of anxiety and depression over the past week. The HADS was completed as per schedule of activities. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.
| units on a scale | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Depression score Week 1 | -0.5 ± 2.71 | 0.0 ± 2.38 | -0.6 ± 2.49 | -0.9 ± 2.94 | -1.0 ± 2.16 |
| Depression score Week 2 | -0.5 ± 2.78 | 0.4 ± 2.99 | -1.1 ± 1.85 | -1.2 ± 2.93 | -1.8 ± 2.66 |
| Depression score Week 4 | -0.5 ± 3.00 | -0.4 ± 3.26 | -0.8 ± 2.05 | -1.5 ± 3.35 | -2.1 ± 3.30 |
| Depression score Week 8 | -0.7 ± 3.31 | -1.3 ± 3.76 | -0.9 ± 2.84 | -2.1 ± 3.35 | -1.7 ± 3.08 |
| Depression score Week 12 | -0.9 ± 3.96 | -0.9 ± 3.65 | -0.5 ± 2.83 | -2.4 ± 3.74 | -1.8 ± 3.90 |
| Depression score Week 14 | 0.1 ± 3.41 | -1.2 ± 3.50 | -0.9 ± 1.53 | -1.7 ± 4.31 | -0.1 ± 4.18 |
| Depression score Week 16 | -0.7 ± 3.18 | -1.1 ± 3.59 | -1.0 ± 1.85 | -1.4 ± 3.93 | -0.1 ± 3.57 |
| Anxiety score Week 1 | -1.0 ± 2.66 | 0.2 ± 2.41 | -0.2 ± 2.49 | -1.1 ± 2.26 | -1.2 ± 2.71 |
| Anxiety score Week 2 | -1.5 ± 2.87 | -0.4 ± 2.56 | -0.9 ± 2.88 | -1.7 ± 2.81 | -2.4 ± 3.15 |
| Anxiety score Week 4 | -1.6 ± 3.18 | -1.0 ± 2.80 | -0.7 ± 2.69 | -1.7 ± 2.95 | -2.4 ± 4.04 |
| Anxiety score Week 8 | -1.7 ± 2.33 | -1.6 ± 2.67 | -1.4 ± 3.21 | -2.7 ± 3.44 | -2.5 ± 3.31 |
| Anxiety score Week 12 | -2.6 ± 3.01 | -1.5 ± 2.85 | -1.0 ± 3.43 | -2.8 ± 3.71 | -2.5 ± 3.51 |
| Anxiety score Week 14 | -2.3 ± 3.43 | -1.5 ± 3.17 | -1.4 ± 2.96 | -2.0 ± 3.49 | -1.5 ± 3.93 |
| Anxiety score Week 16 | -2.9 ± 3.75 | -2.2 ± 3.38 | -0.7 ± 3.27 | -1.4 ± 3.85 | -1.5 ± 3.10 |
Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/56 (0%) | 2/56 (3.6%) | 17/56 (30.4%) |
| PF-04965842 10mg QD | 0/49 (0%) | 2/49 (4.1%) | 18/49 (36.7%) |
| PF-04965842 30mg QD | 0/51 (0%) | 0/51 (0%) | 25/51 (49%) |
| PF-04965842 100mg QD | 0/56 (0%) | 3/56 (5.4%) | 25/56 (44.6%) |
| PF-04965842 200mg QD | 0/55 (0%) | 2/55 (3.6%) | 27/55 (49.1%) |
| Event | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 1/49 | 0/51 | 0/56 | 0/55 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/56 | 1/49 | 0/51 | 1/56 | 0/55 |
| PneumoniaInfections and infestations | 0/56 | 0/49 | 0/51 | 0/56 | 1/55 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/56 | 0/49 | 0/51 | 0/56 | 1/55 |
| Eczema herpeticumInfections and infestations | 0/56 | 0/49 | 0/51 | 1/56 | 0/55 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/56 | 0/49 | 0/51 | 1/56 | 0/55 |
| Dermatitis exfoliativeSkin and subcutaneous tissue disorders | 1/56 | 0/49 | 0/51 | 0/56 | 0/55 |
| Event | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 5/56 | 5/49 | 6/51 | 10/56 | 7/55 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 6/56 | 8/49 | 9/51 | 7/56 | 7/55 |
| NauseaGastrointestinal disorders | 1/56 | 3/49 | 3/51 | 1/56 | 8/55 |
| Upper respiratory tract infectionInfections and infestations | 5/56 | 3/49 | 5/51 | 3/56 | 5/55 |
| HeadacheNervous system disorders | 2/56 | 2/49 | 5/51 | 5/56 | 4/55 |
| DiarrhoeaGastrointestinal disorders | 1/56 | 3/49 | 1/51 | 1/56 | 5/55 |
| DizzinessNervous system disorders | 0/56 | 0/49 | 1/51 | 0/56 | 3/55 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/56 | 0/49 | 0/51 | 3/56 | 0/55 |
The Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study medication.
| Age, Continuous(years) | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD | Total |
|---|---|---|---|---|---|---|
| Mean | 42.6 ± 15.1 | 44.3 ± 15.9 | 37.6 ± 15.9 | 41.1 ± 15.6 | 38.7 ± 17.6 | 40.8 ± 16.1 |
| Sex: Female, Male(Participants) | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD | Total |
|---|---|---|---|---|---|---|
| Female | 35 | 28 | 29 | 25 | 27 | 144 |
| Male | 21 | 21 | 22 | 31 | 28 | 123 |
| Race/Ethnicity, Customized(Participants) | Placebo | PF-04965842 10mg QD | PF-04965842 30mg QD | PF-04965842 100mg QD | PF-04965842 200mg QD | Total |
|---|---|---|---|---|---|---|
| White | 40 | 38 | 39 | 40 | 37 | 194 |
| Black | 10 | 5 | 4 | 7 | 13 | 39 |
| Asian | 4 | 5 | 5 | 8 | 5 | 27 |
| Other | 2 | 1 | 3 | 1 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2016 to primary completion in Mar 2017, 11 months.
Results were first posted in May 2018, 1 year 2 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib